C 6 H 25 Br 3 N 2 O 3 P 2 , triclinic,
. 
Source of material
The title compound was synthesized according to a reported procedure [6] . A mixture of 1,1-dimethyl-3,5-cyclohexanedione (10 mmol), 3, 5-ditri uoromethylbenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino) pyridine (DMAP) (1 mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under vacuum.
Experimental details
Carbon-bound H atoms were placed in calculated positions and were included in the re nement in the riding model approximation. The H atoms of the methyl groups were allowed to rotate with a xed angle around the C-C bond to best t the experimental electron density.
Discussion
The synthesis of pyrans and their derivatives has attracted considerable attention from organic and medicinal chemists for many years as a large number of natural and synthetic products contain this heterocyclic moiety [1] [2] [3] . These compounds possess diverse pharmacological and biological activities such as antitumor, analgesic and ulcerogenic, antiin ammatory, anticoagulant, phototriggering, and fungicidal properties, and can act as anti-pancreatic cancer drug in eliminating cancer related fatigue and maker of pancreatic cancer [4, 5] .
In the crystal structure of the title compound, the pyran ring is nearly planar. In the annulated ring the -CMe 2 group is puckered out of the ring plane (cf. the gure). The pyran ring is almost perpendicular to the (di(tri uoromethyl))phenyl ring.
